TMC207 is a safe and effective drug for the treatment of multidrug-resistant tuberculosis (TB), the results of a randomised, placebo-controlled trial published in the June 4th edition of the New England Journal of Medicine have shown. Patients who received the drug were significantly more likely to have a negative culture...
treatment News
SAN DIEGO – Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center at the 65th American Society of Hematology (ASH)...
—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline— —Brensocatib is Currently Under Priority...
Baltimore, Maryland – A so-called pathological protein long associated with Parkinson’s disease has been found in a new study to trigger cells to increase protein synthesis, an event that eventually kills the subset of brain cells that die off in this neurodegenerative condition. Researchers from the Johns Hopkins University School...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated...
COPENHAGEN, Denmark – Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter transformation (RT), a rare complication in which chronic lymphocytic leukemia (CLL) evolves into an aggressive lymphoma, most often diffuse...
BERLIN, Germany – Lambert-Eaton myasthenic syndrome (LEMS) can be caused by several types of cancer, not just the small-cell lung cancer (SCLC) that’s commonly associated with the immune system disease, according to new data from a European LEMS registry. These data showed that, compared with autoimmune LEMS, which occurs on its...
CONCORD, Mass. — ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced that results on givinostat for the treatment of Duchenne muscular dystrophy (DMD) are being presented at the 2025 Neuromuscular Study Group (NMSG) Annual Scientific Meeting held September 26-28 in Stresa, Italy. Poster presentations include analyses of functional outcomes based on weight-based flexible...
New York, NY – Addressing Brain Health in Adults With Intellectual Disabilities and Developmental Disabilities: A Companion to the KAER Toolkit for Primary Care Providers is a new publication from the Gerontological Society of America (GSA) designed to address the needs of adults with intellectual and developmental disabilities (I/DD) who...
TEL AVIV, Israel — SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD)...